Browsing by Author Knox, S

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 6 of 6
TitleAuthor(s)Issue DateViews
 
Analysis of longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open label extension study
Proceeding/Conference:Hepatology
Jacobson, IMMa, XNguyen, TSchiff, ERYuen, RMFHann, HWLSulkowski, MSNahass, RGRamji, AAgarwal, KPark, JSAyoub, WSGane, EJKnox, SAlves, KLi, YFStamm, LMWeilert, FBennett, MHan, SHBRavendhran, NChan, SKwo, PYElkhashab, MHassanein, TFung, SKBae, HLalezari, JPDieterick, DT
2020
12
 
Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
Proceeding/Conference:Journal of Hepatology
Fung, SSulkowski, MLalezari, JSchiff, ERDieterich, DHassanein, TKwo, PElkhashab, MNahass, RAyoub, WHan, SHBonacini, MAlves, KZayed, HHuang, QColonno, RKnox, SRamji, ABennett, MGane, ERavendhran, NPark, JJacobson, IBae, HChan, SHann, HWMa, XNguyen, TYuen, RMF
2020
 
Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KMa, XNguyen, TSchiff, ERHann, HWDieterich, DNahass, RPark, JChan, SHan, SHGane, EBennett, MAlves, KZayed, HHuang, QColonno, RKnox, SStamm, LBonacini, MJacobson, IAyoub, WWeilert, FRavendhran, NRamji, AKwo, PElkhashab, MHassanein, TBae, HLalezari, JFung, SSulkowski, M
2020
40
 
Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection
Proceeding/Conference:Journal of Hepatology
Agarwal, KNiu, JDing, YGane, ENguyen, TAlves, KEvanchick, MZayed, HHuang, QKnox, SStamm, LColonno, RHassanein, TKim, DJLim, YSYuen, RMF
2020
 
Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients
Proceeding/Conference:Hepatology
Sulkowski, MSAgarwal, KFung, SKYuen, RMFMa, XLLalezari, JPNguyen, TTBae, HSSchiff, ERHassanein, THann, HWLElkhashab, MDieterich, DTKwo, PYNahass, RRamji, APark, JSRavendhran, NChan, SWeilert, FHan, SHBAyoub, WSGane, EJJacobson, IMBennett, MBonacini, MZayed, HAlves, KHuey, VHuang, QRuby, EQiang, DMKnox, SColonno, R
2019
53
 
The second-generation hepatitis B virus (HBV) core inhibitor (CI) ABI-H2158 is associated with potent antiviral activity in a 14-day monotherapy study in HBeAg-positive patients with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Yuen, RMFAgarwal, KGane, EJNguyen, TTHassanein, TKim, DJAlves, KZayed, HQiang, DMRuby, EEvanchik, MHuang, QKnox, SColonno, Ron behalf of ABI-H2158 Study Team
2019
29
Showing results 1 to 6 of 6